Treatment for relapsed acute promyelocytic leukemia Masamitsu Yanada Review Article 16 August 2022 Pages: 2575 - 2582
TLS/FUS-ERG fusion gene in acute leukemia and myelodysplastic syndrome evolved to acute leukemia: report of six cases and a literature review Heyang ZhangQianru ZhanLijun Zhang Review Article Open access 01 October 2022 Pages: 2583 - 2600
Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature Adeel MasoodQamar IqbalHamza Hashmi Review Article 10 October 2022 Pages: 2601 - 2610
Iron chelation of hetrombopag in aplastic anemia: a post hoc analysis of a phase II study Wenrui YangXin ZhaoFengkui Zhang Original Article 11 October 2022 Pages: 2611 - 2616
Clinical characteristics and prognostic factors in intracranial hemorrhage patients with hematological diseases Jia-Yuan ZhangYing LiDa-Peng Li Original Article Open access 30 September 2022 Pages: 2617 - 2625
Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy Allen GreenYu-Min P. ShenSean G. Yates Original Article 04 October 2022 Pages: 2627 - 2631
Luspatercept (RAP-536) modulates oxidative stress without affecting mutation burden in myelodysplastic syndromes Meunier MathieuChloé FriedrichSophie Park Original Article 05 October 2022 Pages: 2633 - 2643
The new diagnostic criteria for myelodysplasia-related acute myeloid leukemia is useful for predicting clinical outcome: comparison of the 4th and 5th World Health Organization classifications Hee Sue ParkHee Kyung KimJihyun Kwon Original Article 12 October 2022 Pages: 2645 - 2654
Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms Milena KalmerKristina PannenNicolas Chatain Original Article Open access 21 October 2022 Pages: 2655 - 2663
Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels Krzysztof LewandowskiZuzanna KandułaPiotr Kozlowski Original Article Open access 21 October 2022 Pages: 2665 - 2677
Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003) Hongmei JingLi YangJie Jin Original Article Open access 27 October 2022 Pages: 2679 - 2690
Is comprehensive geriatric testing guiding in the identification of multiple myeloma patients who are candidates for autologous stem cell transplantation? A prospective analysis Kübra Durmuş DemirelZübeyde Nur ÖzkurtMünci Yağci Original Article 05 October 2022 Pages: 2691 - 2697
Clinical and prognostic role of 2-[18F]FDG PET/CT and sarcopenia in treatment-naïve patients with T-cell lymphoblastic lymphoma Xiaoyue TanHui YuanLei Jiang Original Article 19 September 2022 Pages: 2699 - 2709
Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection Panagiotis T. DiamantopoulosChristina-Nefeli KontandreopoulouNora-Athina Viniou Original Article Open access 22 October 2022 Pages: 2711 - 2717
Dose-finding trial of azacitidine as post-transplant maintenance for high-risk MDS: a KSGCT prospective study Yuho NajimaTakayoshi TachibanaYoshinobu Kanda Original Article 23 September 2022 Pages: 2719 - 2729
Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients Ting-Ting YangXiao-Lu SongJi-Min Shi Original Article 01 November 2022 Pages: 2731 - 2741
Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil Kazuki SakatokuSung-Won KimEisei Kondo Original Article 05 October 2022 Pages: 2743 - 2757
Monitoring energy balance through clinical and serum biomarkers in patients with hematologic malignancies undergoing chemotherapy Chang Won LeeInho KimKwan Sik Seo Original Article 22 September 2022 Pages: 2759 - 2769
Identification of GFI1 mutations in adult patients with congenital neutropenia Erasmia BoutakoglouMaksim KlimiankouHelen A. Papadaki Letter to the Editor 16 September 2022 Pages: 2771 - 2773
Chediak Higashi syndrome with pancytopenia: a rare presentation of a rare disease and the role of hair shaft microscopy in the diagnosis Anupa KhanalSubhajit HajraArvind Kumar Gupta Letter to the Editor 16 September 2022 Pages: 2775 - 2776
Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience Emiliano BarbieriMonica MaccaferriMario Luppi Letter to the Editor Open access 15 September 2022 Pages: 2777 - 2779
Safety and efficacy of splenectomy for the treatment of chronic immune thrombocytopenia Artur SaldanhaFernanda A. OrsiPaula Villaca Letter to the Editor 29 September 2022 Pages: 2781 - 2784
Autoimmune manifestations in STAG2-mutated myeloid neoplasms Bahga KatameshAhmad NanaaAref Al-Kali Letter to the Editor 03 October 2022 Pages: 2785 - 2787
Pyrexia of unknown origin—a rare presentation of disseminated leprosy in the bone marrow Gajendra Kumar YadavSubhajit HajraHarish Chandra Letter to the Editor 10 October 2022 Pages: 2789 - 2791
Aspergillus pericardial empyema successfully treated with percutaneous drainage in a patient with invasive pulmonary aspergillosis Luis GorospeJorge Cobos-AlonsoAnabelle Chinea-Rodríguez Letter to the Editor 19 September 2022 Pages: 2793 - 2794
Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab Yosuke MasamotoKazuki TaokaMineo Kurokawa Letter to the Editor 03 October 2022 Pages: 2795 - 2797
Hemoglobin Beth Israel [HBB:c.308A>G (p.Asn103Ser)]: an ultra-rare, low oxygen-affinity, non-methemoglobinemic hemoglobin diagnosed on targeted resequencing as cause of dominantly inherited benign cyanosis Namrata SinghManu JamwalPrashant Sharma Letter to the Editor 01 October 2022 Pages: 2799 - 2801
Preceding polydipsia/polyuria, ataxia, and dysarthria in an adult with mixed histiocytosis (Erdheim Chester disease/Langerhans cell histiocytosis) Takashi MiyoshiShigehisa TamakiShinsaku Imashuku Letter to the Editor 05 October 2022 Pages: 2803 - 2804
Successful treatment of MDR Stenotrophomonas maltophilia-associated pneumonia with cefiderocol-based regimen in a patient with hematological malignancy Emanuela ZappuloFrancesco GrimaldiIvan Gentile Letter to the Editor 27 October 2022 Pages: 2805 - 2806
Dominant susceptibility-weighted imaging features of intravascular large B-cell lymphoma with central nervous system involvement Yinwei YingXuanxuan LiYiping Lu Letter to the Editor 26 October 2022 Pages: 2807 - 2808
Very severe aplastic anemia with papillary thyroid carcinoma: treatment with allo-HSCT—a case report and literature review Jixin FanRunqing LuRong Guo Letter to the Editor 21 October 2022 Pages: 2809 - 2811
Acute fulminant intravascular hemolysis induced by Clostridium perfringens in a symptomatic multiple myeloma patient under immuno-chemotherapy Hideyuki YamamotoYuki MizutaniAkihiro Tomita Letter to the Editor 01 November 2022 Pages: 2813 - 2815
Correction to: Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta‑analysis Fenghua GaoTingting ZhangHuilai Zhang Correction 18 October 2022 Pages: 2817 - 2817
Correction to: Low‑risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera Ana TrigueroAlexandra Pedrazaon behalf of On behalf of the MPN Spanish Group (GEMFIN) Correction 20 October 2022 Pages: 2819 - 2820
